Results 111 to 120 of about 29,053 (244)

Appraising the visibility, relevance and impacts of clinical pharmacology

British Journal of Clinical Pharmacology, Volume 91, Issue 7, Page 1884-1898, July 2025.
Aims Clinical pharmacology (CP) used to be a strong medical and scientific field, but during the last three decades it seems to have lost some of its appeal. We reviewed the visibility, relevance and impact of CP and clinical pharmacologists across the globe and suggest ways to strengthen the discipline to address future pharmacotherapeutic challenges.
Serge Cremers, Samuel L. M. Arnold, Nilima A. Kshirsagar, Catriona Waitt, Olayinka O. Ogunleye, Lars L. Gustafsson   +5 more
wiley   +1 more source

Lead-212 Radiopharmaceuticals for Receptor-Targeted Radionuclide Therapy [PDF]

Journal of Mazandaran University of Medical Sciences
Receptor-targeted radionuclide therapy (RTRT) combines the power of particle-emitting radionuclides with the receptor-targeting capabilities of biomolecules, including antibodies and peptides.
Solmaz Mojarad-Jabali, Sajjad Molavipordanjani   +1 more
doaj  

Therapy with radionuclides, clinical acceptance is overdue

, 2000
L. Lamki
openalex   +1 more source

α_vβ₃ Integrin‐targeting radionuclide therapy and imaging with monomeric RGD peptide [PDF]

, 2008
Mitsuyoshi Yoshimoto, Kazuma Ogawa, Kohshin Washiyama, Naoto Shikano, Hirofumi Mori, Ryohei Amano, Keiichi Kawai   +6 more
openalex   +1 more source

Recurrent Subdural Hematoma: A Case Report of Diagnostic Pitfall of Spontaneous Intracranial Hypotension and Successful Management With Targeted Epidural Blood Patch

Clinical Case Reports, Volume 13, Issue 7, July 2025.
ABSTRACT Spontaneous intracranial hypotension should be considered in subdural hematoma cases without cerebral trauma or underlying disease, particularly among non‐elderly patients. Targeted epidural blood patch is recommended as a first‐line intervention prior to surgical management in cases of spontaneous intracranial hypotension‐induced subdural ...
Lili Chen, Guangyu Ying, Yucong Peng
wiley   +1 more source

Radionuclide therapy with 111In-pentetreoide in five digestive metastatic neuroendocrine tumors (DNET)

, 2000
Thomas Aparicio, Iradj Sobhani, Christian Nguyen, Rachida Lebrahi, Laurent Abramowitz, Dominique Le Guludec, S. Askienazy, M Mignon   +7 more
openalex   +1 more source

A Proposed Methodology to Select Radioisotopes for Use in Radionuclide Therapy [PDF]

, 2009
John Cuaron, Joshua A Hirsch, David Medich, Barry S. Rosenstein, Christopher B. Martel, Ariel E. Hirsch   +5 more
openalex   +1 more source

CD70: An emerging target for integrated cancer diagnosis and therapy

Clinical and Translational Medicine, Volume 15, Issue 7, July 2025.
CD70 is aberrantly overexpressed in diverse tumours with limited normal tissue expression, making it a compelling diagnostic and therapeutic target. Immuno‐PET/CT facilitates tumour detection, staging, and treatment monitoring. Multiple CD70‐targeted therapies are under early evaluation. Rational combination strategies are emerging to enhance antitumor
Jiatao Hu, Jinxin Li, Bo Yang, Siyi Wang, Yi Bao, Yiren Yang, Kun Qiao, Fei Guo, Xinxin Gan, Linhui Wang   +9 more
wiley   +1 more source

RADIATION-HYGIENIC JUSTIFICATION OF OUTPATIENT RADIONUCLIDE THERAPY

Радиационная гигиена, 2015
The possibility of the use of the different therapeutic radiopharmaceuticals labeled with one of the 19 β-γ-emitting radionuclides or 6 α-β-γ-emitting radionuclides in the outpatient regime was identified in the estimateinvestigations.
B. Ja. Narkevich, S. V. Shiryaev, A. N. Klyopov, N. N. Lipanova, Yu. V. Lysak   +4 more
doaj  

Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy [PDF]

, 2009
Cristina Müller, Thomas L. Mindt, Marion de Jong, Roger Schibli   +3 more
openalex   +1 more source